The NEJ009 study also demonstrated that gefitinib combined with carboplatin plus pemetrexed showed a prolongation of PFS in advanced NSCLC patients with EGFR-mutation compared with gefitinib alone. This evidence concerns the gene EGFR and non-small cell lung carcinoma.